Lumoxiti injection is a new medicine for intravenous use for the treatment of adult patients with refractory hairy cell leukemia (HCL) who have received minimum two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and very first drug of this type of treatment for patients with HCL. It … Continue reading Lumoxiti: Treatment for refractory hairy cell leukemia (HCL)